Who is the manufacturer of Bosutinib?

Bosutinib, trade name Bosulif, is a tyrosine kinase inhibitor (TKI) produced by Pfizer. It is mainly used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML). It is a second-generation tyrosine kinase inhibitor designed to overcome resistance to other tyrosine kinase inhibitors (such as imatinib, dasatinib, etc.). Pfizer is the original drug manufacturer of bosutinib, but currently bosutinib is not on the market in mainland China, so it cannot be included in medical insurance and patients can only purchase it through imported channels.

Although the original drug bosutinib is not yet available in the domestic market, it is available in multiple international markets. The international versions of bosutinib include the Turkish version, the European version and the Swiss version. The ingredients of these versions are consistent with the original drug. However, due to drug registration policies and price differences in different countries, patients need to pay special attention to the source and legality of the drug when purchasing.

Among these overseas versions, the Turkish version and the European version are more common, and there may be some differences in price. Some patients can also purchase bosutinib through drug import channels in Hong Kong or other Asian markets. Bosutinib drugs in these markets usually comply with local drug quality standards and are provided through formal sales channels, ensuring the safety and efficacy of the drugs.

Bosutinib, as one of the main representatives of the treatment of chronic myelogenous leukemia, has shown good results in treatment-resistant patients with Ph+ CML. It is especially suitable for those patients who are resistant to other TKI treatments or cannot tolerate their side effects. Although bosutinib has not yet been launched in China, its sales and use experience in the global market provides patients with more treatment options.

Keyword tags: Bosutinib,Bosutinib, manufacturer, Pfizer, Philadelphia Chromosome, chronic myelogenous leukemia, drug import, drug quality

Reference materials:https://www.bosulif.com/